Jaume Pons, Ph.D., is Senior Vice President and Chief Scientific Officer of Rinat in South San Francisco, California. Jaume is charged with advancing Pfizer’s growing capabilities in generating protein-based biotherapeutics. Focused across multiple therapeutic areas, Rinat researchers combine clinical insight with the disciplines of protein engineering, biology and human genetics to pursue potential therapies for key unmet medical needs.
“Being a biotech unit within Pfizer allows us to leverage the scientific freedom of a small company and the resources and scale of a large biopharmaceutical company to bring novel protein-based therapeutics from the bench through to the clinic.”
Senior Vice President and Chief Scientific Officer, Rinat
Jaume Pons, Ph.D., is Senior Vice President and Chief Scientific Officer of Rinat, the biotech unit of Pfizer in South San Francisco, California. In this role, he is responsible for portfolio delivery from idea to clinical development, up to human proof of concept. Dr. Pons also serves as Chief Technology Officer, focused on antibody technologies, and is a member of the Pfizer Worldwide Research and Development leadership team.
Previously, Dr. Pons created and led Rinat’s protein engineering group, and is an inventor of several antibodies that are now in late-stage clinical development, including RN624 (tanezumab) and RN316 (bococizumab). Under his direction, Rinat continues to advance Pfizer’s growing capabilities in generating therapeutic antibodies, and has progressed eight antibodies into the clinic.
Dr. Pons earned his Ph.D. in molecular and cell biology at the Institute on Fundamental Biology, Barcelona, Spain, and his B.S. in biochemistry from Autonoma University of Barcelona. He conducted his postdoctoral studies in antibody engineering at the University of California, Berkeley.